Auto-anticorps anti-p53 et marqueurs sériques, NSE et CYFRA 21-1, dans le cadre des cancers broncho-pulmonaires

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Immuno-analyse & Biologie Specialisee

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/S0923-2532(01)80006-5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Le dosage sérique des anticorps anti-p53: application au cancer colorectal

  2000cited by this paper
• Serum anti-p53 antibodies in patients with lung cancer.

  2000cited by this paper
• Le gène suppresseur de tumeurs TP53 : vingt ans (et dix mille mutations) après

  2000cited by this paper
• Regulation of the p53 Tumor Suppressor Protein*

  1999cited by this paper
• Estimates of the worldwide mortality from 25 cancers in 1990

  1999cited by this paper
• Anticorps sériques anti-p53 : un nouveau marqueur tumoral ?

  1998cited by this paper
• Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma

  1998cited by this paper
• Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer.

  1998cited by this paper
• Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.

  1998cited by this paper
• Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment.

  1998cited by this paper
• P53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy.

  1998cited by this paper
• Serum p53 antibodies as early markers of lung cancer

  1995cited by this paper
• p53 antibodies in patients with various types of cancer: assay, identification, and characterization.

  1995cited by this paper
• Database of p53 gene somatic mutations in human tumors and cell lines.

  1994cited by this paper
• Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein.

  1994cited by this paper
• p53 immunolabeling in archival paraffin-embedded tissues: optimal protocol based on microwave heating for eight antibodies on lung carcinomas.

  1994cited by this paper
• [The p53 gene and protein in bronchial carcinogenesis:from biological to clinical aspects].

  1994cited by this paper
• Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein.

  1994cited by this paper
• P53 mutations in human cancer.

  1993cited by this paper
• p53 protein accumulates frequently in early bronchial neoplasia.

  1993cited by this paper
• Metastatic human pleural ovarian cancer model constructed by orthotopic implantation of fresh histologically-intact patient carcinoma in nude mice.

  1993cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper

• No citing papers are available for this paper.